Panelists discuss how open-label extension studies of VMAT2 inhibitors demonstrate sustained efficacy, tolerability, and patient retention in long-term treatment of tardive dyskinesia—including in older adults—highlighting their potential to improve quality of life despite manageable adverse effects.